Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis
journal contributionposted on 2022-05-20, 03:50 authored by H Liu, G Pietersz, Karlheinz PeterKarlheinz Peter, Xiaowei WangXiaowei Wang
Atherosclerosis and atherothrombosis, the major contributors to cardiovascular diseases (CVDs), represent the leading cause of death worldwide. Current pharmacological therapies have been associated with side effects or are insufficient at halting atherosclerotic progression effectively. Pioneering work harnessing the passive diffusion or endocytosis properties of nanoparticles and advanced biotechnologies in creating recombinant proteins for site-specific delivery have been utilized to overcome these limitations. Since CVDs are complex diseases, the most challenging aspect of developing site-specific therapies is the identification of an individual and unique antigenic epitope that is only expressed in lesions or diseased areas. This review focuses on the pathological mechanism of atherothrombosis and discusses the unique targets that are important during disease progression. We review recent advances in site-specific therapy using novel targeted drug-delivery and nanoparticle-carrier systems. Furthermore, we explore the limitations and future perspectives of site-specific therapy for CVDs. Graphical Abstract: [Figure not available: see fulltext.]
KP is supported by a National Health and Medical Research Council Investigator L3 Fellowship (GNT1174098). XW is supported by a National Heart Foundation Future Leader Fellowship (101932) and a Baker Fellowship.
JournalJournal of Nanobiotechnology
Article NumberARTN 75
Rights Statement© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Read the peer-reviewed publication
Science & TechnologyLife Sciences & BiomedicineBiotechnology & Applied MicrobiologyNanoscience & NanotechnologyScience & Technology - Other TopicsAntibodiesAtherosclerosisGene deliveryNanoparticlesTargeted drug deliveryThrombosisTISSUE-PLASMINOGEN ACTIVATORSIRNA-MEDIATED INHIBITIONABDOMINAL AORTIC-ANEURYSMSERUM LDL-CHOLESTEROLP-SELECTINSCAVENGER RECEPTORSPLAQUE STABILITYTRANSGENIC MICEFUSION PROTEINATHEROSCLEROSISCardiovascular DiseasesDrug Delivery SystemsHumansPharmaceutical Preparations